-
Data & Technology Solutions
Data Capabilities 设计更好的研究 Improve Study Recruitment Reduce Study Risk Gain Operational Insights Ensure Data Quality Access Central Laboratory Information Empower Your Data Maximize Product Access Transform Patient SafetyDevice & Diagnostics
Functional Service Provider (FSP)
-
Commercialization
Market Access and Phase IV Solutions
-
Analysis Services
Bioanalysis DMPK Custom Antibody ReagentsDiscovery
Lead Optimization Non-GLP Toxicology In Vivo Pharmacology Nonclinical Imaging Nonclinical Pathology Services PK/TK Analysis and Reporting Flow Cytometry Radiation Vaccine TestingProduct Testing
Crop Protection Chemical LocationsPathology
Anatomic Clinical Specialty -
Manufacturing Support
CMC AnalyticalToxicology
General Toxicology Studies Genetic Toxicology Immunotoxicology Pathology Pharmacology Developmental and Reproductive Toxicology (DART) Studies SEND 3.1Administration Routes
InhalationConsulting & Partnering
Alliance Management Early Phase Development Solutions Covance MarketPlace Drug Development Consulting -
Data & Technology Solutions
Data Capabilities 设计更好的研究 Improve Study Recruitment Reduce Study Risk Gain Operational Insights Ensure Data Quality Access Central Laboratory Information Empower Your Data Maximize Product Access Transform Patient SafetyClinical Development
Clinical Pharmacology Early Clinical / Phase IIa Phase IIb / III Services Clinical Data Management Analysis and Reporting Regulatory Services Phase IV Clinical Research Unit Virtual Tours Clinical-Biotech Decentralized Clinical Trials -
yaboapp地址
Central Labs Specialty Testing Precision Medicine Bioanalytical CMCFunctional Service Provider (FSPx)
FSP Education CenterCommercialization
Access and Strategy Evidence Generation Value Communication Patient Support Services Phase IV Solutions Patient Safety and Pharmacovigilance Services
-
Call Us
The Americas
+1.888.COVANCE (+1.888.268.2623) 1.609.452.4440Europe/Africa
+00.800.2682.2682 +44.1423.500888Asia/Pacific
+800.6568.3000 +65.6.5686588Global Office Locations
-
Media Relations
Request an Interview Request a Speaker亚博全站官网
设备订购Investors
Investor RelationsJob Seekers
Covance Careers
Eye irritation
Record Type:Evaluation
Models:牛,Other Model,Human
Eye irritation is defined as the production of changes in the eye following the application of a test substance to the anterior surface of the eye. These changes are fully reversible within 21 days of application (UNECE, Part 3.3, 2015). It is a key toxicological endpoint required to achieve fundamental product safety standards and to guide therapy development. There are various eye irritation test models; one example is in vitro bovine corneal opacity and permeability (BCOP) assays. These can be used to screen substances early on in development or during GLP toxicity testing.
Phase
About our nonclinical animal research models: We provide the utmost care for our research animals and actively pursue advances in animal welfare. As well as ensuring the highest scientific, ethical and regulatory standards, selection of appropriate animal research models for development research is critical to developing safe and effective treatments, devices and products that protect and save lives. Just as we have ethical committee oversight for human trials, we have ethical committees overseeing all aspects of our global animal care and use programs. All of our core, nonclinical facilities are accredited by AAALAC.Learn more about our commitment to replacing, reusing and refining nonclinical research models.
Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.